Latest & greatest articles for pregabalin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pregabalin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pregabalin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pregabalin

81. Pregabalin - diabetic peripheral neuropathy

Pregabalin - diabetic peripheral neuropathy Common Drug Review CEDAC Meeting – July 15, 2009; CEDAC Reconsideration – September 16, 2009 Notice of CEDAC Final Recommendation – September 23, 2009 Page 1 of 5 © 2009 CADTH CEDAC FINAL RECOMMENDATION PREGABALIN RESUBMISSION (Lyrica ® – Pfizer Canada Inc.) Indication: Neuropathic Pain Associated with Diabetic Peripheral Neuropathy Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that pregabalin not be listed. Reasons (...) for the Recommendation: 1. The Committee considered the results of three new randomized placebo-controlled trials of pregabalin in patients with diabetic peripheral neuropathy that met the CDR protocol since the original review. Two of the three trials did not show a statistically significant reduction in mean pain scores at study endpoint for pregabalin compared with placebo. 2. There are a number of drug classes used in the treatment of pain associated with diabetic peripheral neuropathy, including tricyclic

2009 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

82. Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials

Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

83. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain

Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

84. A randomized controlled trial of perioperative administration of pregabalin for pain after laparoscopic hysterectomy (PubMed)

A randomized controlled trial of perioperative administration of pregabalin for pain after laparoscopic hysterectomy Pregabalin has anticonvulsant, antihyperalgesic, and anxiolytic properties. In this study we evaluated the control of pain after perioperative administration of pregabalin 300 or 600 mg, compared with diazepam 10mg. Altogether 91 women scheduled for laparoscopic hysterectomy were randomized to receive diazepam 10mg (D10), pregabalin 150 mg (P300) or 300 mg (P600 (...) surgery was smaller in the P600 group than in the P300 group (0.09 vs. 0.16 mg kg(-1); P=0.025). The total dose of oxycodone (0-24h after surgery) was smaller in the P600 group than in the D10 group (0.34 vs. 0.45 mg kg(-1); P=0.046). The incidence of dizziness (70% vs. 35%; P=0.012), blurred vision (63% vs. 14%; P=0.002) and headache (31% vs. 7%; P=0.041) were higher in the P600 group than in the D10 group. In conclusion, perioperative administration of pregabalin 600 mg decreases oxycodone

2008 EvidenceUpdates

85. Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder

Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder Article Text Therapeutics Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder Statistics from Altmetric.com Request Permissions If you

2008 Evidence-Based Mental Health

86. Pregabalin add-on for drug-resistant partial epilepsy. (Full text)

Pregabalin add-on for drug-resistant partial epilepsy. Epilepsy is a common chronic neurological disease with an estimated prevalence of 1% in the United Kingdom. Approximately a third of these people continue to have seizures despite drug treatment. In order to try to improve outcomes a number of new antiepileptic drugs have been developed and pregabalin is one of these.To summarize evidence from randomized, controlled trials regarding the efficacy and tolerability of pregabalin when used (...) as an add-on antiepileptic drug in treatment-resistant partial epilepsy.We searched the Cochrane Epilepsy Group Specialized Register (July 2007), The Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 2, 2007), Medline (1966 to March 2007) and contacted Pfizer Inc (the manufacturers of pregabalin) to identify published, unpublished, and ongoing trials.We included randomized controlled double-blind trials comparing pregabalin with placebo for people with drug-refractory partial

2008 Cochrane PubMed

87. Pregabalin as a treatment for painful diabetic peripheral neuropathy: a meta-analysis

Pregabalin as a treatment for painful diabetic peripheral neuropathy: a meta-analysis Pregabalin as a treatment for painful diabetic peripheral neuropathy: a meta-analysis Pregabalin as a treatment for painful diabetic peripheral neuropathy: a meta-analysis Hurley RW, Lesley MR, Adams MC, Brummett CM, Wu CL CRD summary The authors concluded that pregabalin significantly decreased the effects of pain associated with diabetic peripheral neuropathy in comparison to placebo. The use of systematic (...) review methodology and consistency of effects suggested that the conclusions were robust, but the generalisability of the results was unclear given the small sample sizes and reliability may be compromised by the process of study selection. Authors' objectives To compare the efficacy of pregabalin and placebo in the treatment of diabetic peripheral neuropathy (DPN). Searching PubMed and EMBASE were searched from 1966 to 2007 to identify relevant studies. References of relevant abstracts were checked

2008 DARE.

88. Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a German perspective

Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a German perspective Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a German perspective Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a German perspective Liedgens H (...) and pregabalin for the treatment of patients with post-herpetic neuralgia. The authors concluded that the lidocaine plaster was the most cost-effective treatment. The methodology had several limitations, so the authors' conclusions should be treated with caution. Type of economic evaluation Cost-effectiveness analysis, cost-utility analysis Study objective The aim was to assess the cost-effectiveness of four options for the treatment of post-herpetic neuralgia in patients who did not experience pain relief

2008 NHS Economic Evaluation Database.

89. Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy (Full text)

Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy Vera-Llonch M, Brandenburg N A, Oster G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of pregabalin as an additional therapy in comparison with usual care in patients with refractory partial epilepsy. The authors concluded that the cost-effectiveness of pregabalin compared favourably with the published estimates of the cost-effectiveness of other add-on antiepileptic drugs. The study

2008 NHS Economic Evaluation Database. PubMed

90. A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain

A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain Annemans L, Caekelbergh K, Morlion B, Hans G, De Cock P, Marbaix S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of pregabalin added to usual care, compared with usual care alone, for the treatment of peripheral neuropathic pain. The authors concluded that pregabalin led to a small, but significant, improvement in patient health without increasing costs from the perspective of the Belgian health care payer. In general, the quality

2008 NHS Economic Evaluation Database.

91. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia

Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

92. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective

Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian (...) ) and postherpetic neuralgia (PHN). The treatments were gabapentin (between 900 and 3,600 mg/day) and pregabalin (between 150 and 600 mg/day). In particular, the analysis focused, in the base-case, on a dosage of 2,400 mg for gabapentin and 430 mg for pregabalin. Type of intervention Treatment. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population The study population comprised two hypothetical cohorts, one of patients with DPN and one of patients with PHN. Only patients

2006 NHS Economic Evaluation Database.

93. pregabalin

pregabalin CEDAC FINAL RECOMMENDATION on RECONSIDERATION and REASONS for RECOMMENDATION PREGABALIN (Lyrica - Pfizer Canada Inc.) Description: Pregabalin is approved for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN). Dosage Forms: 25 mg, 50 mg, 75 mg, 150 mg and 300 mg capsules Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that pregabalin not be listed. Reasons for the Recommendation: 1 (...) . The Committee considered the results of 12 randomized controlled trials (RCTs), 6 in painful DPN, 5 in PHN and 1 in a mixed painful DPN and PHN population. With the exception of 1 RCT in painful DPN that included amitriptyline as a comparator, all trials were placebo controlled and of relatively short duration ( =13 weeks). The lack of RCTs comparing pregabalin to other therapies makes it very difficult to determine the relative efficacy and safety of pregabalin. 2. Compared to placebo, pregabalin produced

2006 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

94. High dose pregabalin is effective for the treatment of generalised anxiety disorder (Full text)

High dose pregabalin is effective for the treatment of generalised anxiety disorder High dose pregabalin is effective for the treatment of generalised anxiety disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here High dose pregabalin is effective for the treatment of generalised anxiety disorder Article Text Therapeutics High dose pregabalin is effective for the treatment of generalised anxiety disorder Free Raymond Pary , MD

2005 Evidence-Based Mental Health PubMed

95. Lyrica (Pregabalin) Capsules

Lyrica (Pregabalin) Capsules Drug Approval Package: Lyrica (Pregabalin) NDA #021724 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Lyrica (Pregabalin) Capsules Company: Pfizer Inc. Application No.: 021724 Approval Date: 06/10/2005 (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: January 23, 2008 Note: Documents in PDF format require the . - - Links on this page: Note: If you need help accessing

2005 FDA - Drug Approval Package

96. Pregabalin for peripheral neuropathic pain

Pregabalin for peripheral neuropathic pain Pregabalin for peripheral neuropathic pain Pregabalin for peripheral neuropathic pain Hadj Tahar A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hadj Tahar A. Pregabalin for peripheral neuropathic pain. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2005: 4 (...) Authors' objectives The aim of this report is to review the available information on the use of pregabalin (Trade Mark: Lyrica), an anticonvulsant drug, in the treatment of adults with peripheral neuropathic pain (NeP). Authors' conclusions The costs associated with pregabalin treatment may not compare favourably with that of generic gabapentin. However, gabapentin is not approved for the treatment of NeP by Health Canada. While pregabalin appears to be an effective treatment for NeP

2005 Health Technology Assessment (HTA) Database.

97. Lyrica (Pregabalin)

Lyrica (Pregabalin) Drug Approval Package: Lyrica (Pregabalin) NDA #021446 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Lyrica (Pregabalin) Capsules Company: Pfizer Gloval Research & Development Application No.: 021446 Approval Date: 12/30/2004 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: July 192005 Note: Documents in PDF format require the . - - Links on this page: Note: If you need help accessing information in different file formats

2004 FDA - Drug Approval Package